ADBICA

ADBICA
Clinical data
ATC code none
Legal status
Legal status
Identifiers
CAS Number 1445583-48-1 YesY
PubChem (CID) 72710773
ChemSpider 29342130
UNII Q71G788A6H
Chemical and physical data
Formula C20H29N3O2
Molar mass 343.46 g/mol
3D model (Jmol) Interactive image

ADBICA (also known as ADB-PICA) is a designer drug identified in synthetic cannabis blends in Japan in 2013.[1] ADBICA had not previously been reported in the scientific literature prior to its sale as a component of synthetic cannabis blends. ADBICA features a carboxamide group at the 3-indole position, like SDB-001 and STS-135. The stereochemistry of the tert-butyl side-chain in the illicitly sold product is unresolved, though in a large series of indazole derivatives structurally similar to ADBICA that are disclosed in Pfizer patent WO 2009/106980, activity resides exclusively in the (S) enantiomers.[2] ADBICA is a potent agonist of the CB1 receptor and CB2 receptor with a EC50 value of 0.69 nM and 1.8 nM respectively.[3]

Legal Status

As of October 2015 ADBICA is a controlled substance in China.[4]

See also

References

  1. Uchiyama, N.; Matsuda, S.; Kawamura, M.; Kikura-Hanajiri, R.; Goda, Y. (2013). "Two new-type cannabimimetic quinolinyl carboxylates, QUPIC and QUCHIC, two new cannabimimetic carboxamide derivatives, ADB-FUBINACA and ADBICA, and five synthetic cannabinoids detected with a thiophene derivative α-PVT and an opioid receptor agonist AH-7921 identified in illegal products". Forensic Toxicology. 31: 223–240. doi:10.1007/s11419-013-0182-9.
  2. Buchler IP et al, INDAZOLE DERIVATIVES. WO 2009/106980
  3. Samuel D Banister; Michael Moir; Jordyn Stuart; Richard C Kevin; Katie E Wood; Mitchell Longworth; Shane M Wilkinson; Corinne Beinat; Alxendra S Buchanan; Michelle Glass; Mark Connor; Iain S McGregor; Michael Kassiou (July 2015). "The pharmacology of indole and indazole synthetic cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA and 5F-ADBICA". ACS Chemical Neuroscience. 6: 1546–59. doi:10.1021/acschemneuro.5b00112. PMID 26134475.
  4. "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Retrieved 1 October 2015.


This article is issued from Wikipedia - version of the 8/1/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.